Pfirrmann, M., Saußele, S., & Hehlmann, R. (2017). No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: Results in 1494 patients with chronic myeloid leukemia treated with imatinib. Journal of cancer research and clinical oncology, 143(5), . https://doi.org/10.1007/s00432-016-2321-2
Chicago-Zitierstil (17. Ausg.)Pfirrmann, Markus, Susanne Saußele, und Rüdiger Hehlmann. "No Influence of BCR-ABL1 Transcript Types E13a2 and E14a2 on Long-term Survival: Results in 1494 Patients with Chronic Myeloid Leukemia Treated with Imatinib." Journal of Cancer Research and Clinical Oncology 143, no. 5 (2017). https://doi.org/10.1007/s00432-016-2321-2.
MLA-Zitierstil (9. Ausg.)Pfirrmann, Markus, et al. "No Influence of BCR-ABL1 Transcript Types E13a2 and E14a2 on Long-term Survival: Results in 1494 Patients with Chronic Myeloid Leukemia Treated with Imatinib." Journal of Cancer Research and Clinical Oncology, vol. 143, no. 5, 2017, https://doi.org/10.1007/s00432-016-2321-2.